CA2317744A1 - Cellulose derivatives and colorectal cancer risk reduction - Google Patents
Cellulose derivatives and colorectal cancer risk reduction Download PDFInfo
- Publication number
- CA2317744A1 CA2317744A1 CA002317744A CA2317744A CA2317744A1 CA 2317744 A1 CA2317744 A1 CA 2317744A1 CA 002317744 A CA002317744 A CA 002317744A CA 2317744 A CA2317744 A CA 2317744A CA 2317744 A1 CA2317744 A1 CA 2317744A1
- Authority
- CA
- Canada
- Prior art keywords
- fiber
- fermentable
- methylcellulose
- soluble
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is a method of reducing the incidence of colorectal cancers in a mammal in need thereof, which method comprises administering to said mammal a water-soluble, non-fermentable cellulose derivative, alone or in combination with an insoluble fiber and/or a soluble fermentable fiber.
Description
CELLULOSE DERIVATIVES AND COLORECTAL CANCER RISK
REDUCTION
FIELD OF INVENTION
The present invention is directed to the risks associated with colorectal cancers and dietary components.
BACKGROUND OF THE INVENTION
Colorectal cancer is a common and serious medical condition. The incidence of colon cancer is roughly the same in men and women; rectal cancer is somewhat more common in men. Epidemiological studies have shown that when populations have migrated from areas of low incidence (e.g., Eastern Europe or Asia) to an area of higher incidence (the U.S.), their incidence of colorectal cancers increases to U.S.
rates within 10-15 years. This suggests that dietary factors play a role in the incidence of colorectal cancers. Indeed, various epidemiological studies which have attempted to relate diet composition to relative risk of colon cancer. Dietary fat 2o intake appears to be positively correlated to risk. Dietaxy fiber also appears to play a role, although this may not be true for all types of fiber. The epidemiological studies may produce inconsistent results because they do not control for all components for the diet. For example, are high fiber diets protective because foods high in fiber also tend to be low in fat and high in antioxidants? Despite such difficulties in interpreting the data, many health authorities have recommended that dietary fiber intake be roughly doubled to 25-30 g/day. This objective is reflected in the National Academy of Science health goal calling for individuals to consume five or more servings of fruit and six or more servings of breads, cereals and legumes every day.
[References for above: Committee on Diet & Health, Food & Nutrition Board, 3o Commission on Life Sciences, National Research Council. Diet and Health.
Implications for Reducing Chronic Disease Risk. National Academy Press, Washington, D.C., 1989; and R. B. Sause. 1995. Health Implications ofDietary Fiber. US Pharmacist, Feb. issue.]
Animal studies employing known colon carcinogens have enabled researchers 3s to study dietary components under more controlled conditions. These studies have shown the protective effects for certain sources of insoluble fiber (e.g., wheat bran) and certain soluble, fermentable fibers (e.g., psyllium), as well as other dietary components such as calcium and certain vitamins [Alabaster et al., Dietary fiber and the chemoprotective modulation of colon carcinogenesis. Mutat Res 1996 Feb 19;
350(1):185-197.] Some studies have shown increased protection from combining wheat bran and psyllium in a colon cancer model [Alabaster et al., Cancer Lett Nov 30;75(1):53-58J and in a breast cancer model [Cohen et al., J Natl Cancer Inst 1996 Jul 3;88(13):899-907.).
However a need still exists for additional dietary components for the prophylactic treatment of colorectal cancers.
to SUMMARY OF THE INVENTION
The present invention is to a method of reducing the incidence of colorectal cancers in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a water soluble, non-fermentable cellulose derivative, alone or in combination with an insoluble fiber and/or a soluble fermentable fiber.
DETAILED DESCRIPTION OF THE INVENTION
The protective effects of water soluble, non-fermentable cellulose derivatives (e.g., methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl-methylcellulose) for use as a dietary component for colon cancer risk reduction 2o appears to have not been the subject of previous studies in this area.
These semi-synthetic fibers have been in the food supply for decades, and are considered safe, but the beneficial clinical effects of these fibers have rarely been considered outside the area of laxation.
Some studies have investigated the ability of cellulose derivatives to lower plasma cholesterol or improve glycemic control, but have not been used in cancer models, except as vehicles to suspend poorly soluble carcinogens. These fibers have properties which are unique relative to the naturally occurring food fibers.
They are 100% water soluble (in cool water; they become insoluble in hot water), and they are non-fermentable. Naturally occurnng soluble fibers such as pectin, psyllium, and 3o guar gum, are fermentable in the human GI tract, essentially completely in the case of pectin or guar, and to a significant extent (~50%) in the case of psyllium.
It has been hypothesized that the fermentation products, particularly the short chain fatty acid butyrates, may be responsible for the protective effect of these soluble fibers. However, there are additional proposed mechanisms which would result in cellulose derivatives showing this benefit. These include, but are not limited to, dilution of carcinogens in the GI tract, and decreasing residence time of carcinogens in the GI tract (either by speeding transit of carcinogens or by elimination of pro-carcinogens prior to their conversion to carcinogens). Both the dilution and faster transit effects are caused by the ability of the fibers to resist degradation and hold water. The gut contents are made both bulkier and softer through this action, and the propulsive motility of the gut is more effective with softer material.
Therefore, the water-soluble cellulose derivatives (e.g., methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose) would show a benefit in reducing the incidence of colon cancers.
The present invention has found, unexpectently that the combination of 1o psyllium plus wheat bran was less effect than wheat bran alone or in combination with a water soluble cellulose derivative, such as methylcellulose. This combination of methylcellulose and wheat bran is more effective that the widely accepted protective fiber, and better than the previously published combination therapy.
Furthermore, the present invention, as shown below, also supports the proposition 15 that enhanced protection is obtained by use of methylcellulose atone.
BIOLOGICAL EXPERIMENTS
Standard animal models may be employed to demonstrate the protective effect of cellulose derivatives against colon and other cancers.
2o Experimental and epidemiological evidence suggest that increased dietary fiber is associated with decreased breast cancer risk. Little is known about the role played by different types of fiber and, particularly, mixtures of soluble and insoluble fibers similar to those consumed by human populations in reducing breast cancer risk. High intake of fiber may suppress bacterial hydrolysis of biliary estrogen 25 conjugates to free (absorbable) estrogens in the colon and thus may decrease the availability of circulating estrogens necessary for the development and growth of breast cancers.
Example 1 30 An example of one such published colon tumor study as applied to psyllium and wheat bran is shown below. Using this model, but with methylcellulose, alone or in combination with wheat bran is proposed. The primary measure to demonstrate the benefit thereof would be the number of preneoplastic aberrant crypt foci.
Alabaster et al., Cancer Lett 1993 Nov 30;75(1):53-58 Potential synergism 35 between wheat bran and psyllium: enhanced inhibition of colon cancer, whose disclosure is incorporated by reference herein in its entirety.
REDUCTION
FIELD OF INVENTION
The present invention is directed to the risks associated with colorectal cancers and dietary components.
BACKGROUND OF THE INVENTION
Colorectal cancer is a common and serious medical condition. The incidence of colon cancer is roughly the same in men and women; rectal cancer is somewhat more common in men. Epidemiological studies have shown that when populations have migrated from areas of low incidence (e.g., Eastern Europe or Asia) to an area of higher incidence (the U.S.), their incidence of colorectal cancers increases to U.S.
rates within 10-15 years. This suggests that dietary factors play a role in the incidence of colorectal cancers. Indeed, various epidemiological studies which have attempted to relate diet composition to relative risk of colon cancer. Dietary fat 2o intake appears to be positively correlated to risk. Dietaxy fiber also appears to play a role, although this may not be true for all types of fiber. The epidemiological studies may produce inconsistent results because they do not control for all components for the diet. For example, are high fiber diets protective because foods high in fiber also tend to be low in fat and high in antioxidants? Despite such difficulties in interpreting the data, many health authorities have recommended that dietary fiber intake be roughly doubled to 25-30 g/day. This objective is reflected in the National Academy of Science health goal calling for individuals to consume five or more servings of fruit and six or more servings of breads, cereals and legumes every day.
[References for above: Committee on Diet & Health, Food & Nutrition Board, 3o Commission on Life Sciences, National Research Council. Diet and Health.
Implications for Reducing Chronic Disease Risk. National Academy Press, Washington, D.C., 1989; and R. B. Sause. 1995. Health Implications ofDietary Fiber. US Pharmacist, Feb. issue.]
Animal studies employing known colon carcinogens have enabled researchers 3s to study dietary components under more controlled conditions. These studies have shown the protective effects for certain sources of insoluble fiber (e.g., wheat bran) and certain soluble, fermentable fibers (e.g., psyllium), as well as other dietary components such as calcium and certain vitamins [Alabaster et al., Dietary fiber and the chemoprotective modulation of colon carcinogenesis. Mutat Res 1996 Feb 19;
350(1):185-197.] Some studies have shown increased protection from combining wheat bran and psyllium in a colon cancer model [Alabaster et al., Cancer Lett Nov 30;75(1):53-58J and in a breast cancer model [Cohen et al., J Natl Cancer Inst 1996 Jul 3;88(13):899-907.).
However a need still exists for additional dietary components for the prophylactic treatment of colorectal cancers.
to SUMMARY OF THE INVENTION
The present invention is to a method of reducing the incidence of colorectal cancers in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a water soluble, non-fermentable cellulose derivative, alone or in combination with an insoluble fiber and/or a soluble fermentable fiber.
DETAILED DESCRIPTION OF THE INVENTION
The protective effects of water soluble, non-fermentable cellulose derivatives (e.g., methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl-methylcellulose) for use as a dietary component for colon cancer risk reduction 2o appears to have not been the subject of previous studies in this area.
These semi-synthetic fibers have been in the food supply for decades, and are considered safe, but the beneficial clinical effects of these fibers have rarely been considered outside the area of laxation.
Some studies have investigated the ability of cellulose derivatives to lower plasma cholesterol or improve glycemic control, but have not been used in cancer models, except as vehicles to suspend poorly soluble carcinogens. These fibers have properties which are unique relative to the naturally occurring food fibers.
They are 100% water soluble (in cool water; they become insoluble in hot water), and they are non-fermentable. Naturally occurnng soluble fibers such as pectin, psyllium, and 3o guar gum, are fermentable in the human GI tract, essentially completely in the case of pectin or guar, and to a significant extent (~50%) in the case of psyllium.
It has been hypothesized that the fermentation products, particularly the short chain fatty acid butyrates, may be responsible for the protective effect of these soluble fibers. However, there are additional proposed mechanisms which would result in cellulose derivatives showing this benefit. These include, but are not limited to, dilution of carcinogens in the GI tract, and decreasing residence time of carcinogens in the GI tract (either by speeding transit of carcinogens or by elimination of pro-carcinogens prior to their conversion to carcinogens). Both the dilution and faster transit effects are caused by the ability of the fibers to resist degradation and hold water. The gut contents are made both bulkier and softer through this action, and the propulsive motility of the gut is more effective with softer material.
Therefore, the water-soluble cellulose derivatives (e.g., methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose) would show a benefit in reducing the incidence of colon cancers.
The present invention has found, unexpectently that the combination of 1o psyllium plus wheat bran was less effect than wheat bran alone or in combination with a water soluble cellulose derivative, such as methylcellulose. This combination of methylcellulose and wheat bran is more effective that the widely accepted protective fiber, and better than the previously published combination therapy.
Furthermore, the present invention, as shown below, also supports the proposition 15 that enhanced protection is obtained by use of methylcellulose atone.
BIOLOGICAL EXPERIMENTS
Standard animal models may be employed to demonstrate the protective effect of cellulose derivatives against colon and other cancers.
2o Experimental and epidemiological evidence suggest that increased dietary fiber is associated with decreased breast cancer risk. Little is known about the role played by different types of fiber and, particularly, mixtures of soluble and insoluble fibers similar to those consumed by human populations in reducing breast cancer risk. High intake of fiber may suppress bacterial hydrolysis of biliary estrogen 25 conjugates to free (absorbable) estrogens in the colon and thus may decrease the availability of circulating estrogens necessary for the development and growth of breast cancers.
Example 1 30 An example of one such published colon tumor study as applied to psyllium and wheat bran is shown below. Using this model, but with methylcellulose, alone or in combination with wheat bran is proposed. The primary measure to demonstrate the benefit thereof would be the number of preneoplastic aberrant crypt foci.
Alabaster et al., Cancer Lett 1993 Nov 30;75(1):53-58 Potential synergism 35 between wheat bran and psyllium: enhanced inhibition of colon cancer, whose disclosure is incorporated by reference herein in its entirety.
Using this model, but modifying to include methylcellulose instead of psyllium, the following study compares the influence of high fat (20% w/w) diets that combine low levels of calcium (0.18% w/w) and low (1% w/w), medium (4%
w/w) and high (8% w/w) levels of dietary fiber from wheat bran (WB), with high s (8% w/w or >) levels of dietary fiber from a water soluble cellulose derivative (WS) alone or in various combinations with WB, on the induction of colon tumors in Fischer-344 rats following exposure to azoxymethane (AOM). The rats are fed the experimental diets for 2 weeks, and then are given two subcutaneous.
injections of AOM (15 mg/kg body wt./week). Twenty-three weeks following the first injection to of AOM, the incidence of colon tumors in the different dietary groups (12 rats/group) is compared.
In the Alabaster study, results showed that by increasing the dietary fiber concentration of WB from 1 to 8% significantly reduced the number of colon tumors/group. When the influence of 8% dietary fiber from WB on the development 15 of colon tumors was compared with that of psyllium (PS) (WB:PS = 0:100), no significant difference was observed. However, combinations of WB and PS showed a greater protective effect than either WB or PS alone, at comparable levels of dietary fiber. The 50:50 combination of WB and PS showed maximum protection, while 25:75 and 75:25 combinations both produced intermediate effects. None of 2o the diets showed any significant effect on the normal growth of rats. The results indicate that WB and PS fiber alone, and to a greater degree in combination, can offer protection against colon cancer promoted by high fat, low calcium diets.
Therefore, diets that include wheat bran in combination with a water soluble 25 cellulose derivative could be an effective means of reducing colon cancer risk in human populations addicted to high risk western diets.
Example 2 The protective benefit in breast cancer of water soluble fibers could be 3o demonstrated with a study design such as the following. The primary efficacy measures would be total tumor number and multiplicity of mammary adenocarcinomas.
A suitable model for this is the study is shown in Cohen et al., J Natl Cancer Inst 1996 Jul 3;88(13):899-907 Wheat bran and psyllium diets: effects on N-35 methylnitrosourea-induced mammary tumorigenesis in F344 rats, whose disclosure is incorporated by reference herein in its entirety. Using this model but instead substituting a suitable water soluble fiber as taught herein.
This study can evaluate the effect of wheat bran {an insoluble fiber) and a water soluble cellulose (a soluble fiber) alone and in combination on overall estrogen status, on fecal bacterial beta-D-glucuronidase (a key diet-responsive estrogen-deconjugating enzyme) activity, and on the induction of mammary tumors in rats treated with N-methylnitrosourea (~.
1o Methods: One hundred fifty virgin female F344 rats are fed the NIH-07 diet from 28 days of age until 50 days of age; they are then given a single dose (40 mg/kg of body weight) of MNU by tail vein injection. Three days later, they are randomly assigned to one of five experimental dietary groups (30 animals per group).
Soft, white wheat bran (45% dietary fiber content) and water soluble cellulose is added to 15 a modified (high-fat) American Institute of Nutrition (AIN)-76A diet at the following percents, respectively: 12% + 0% (group 1), 8% + 2% (group 2), 6% +
3% (group 3), 4% + 4% (group 4), and 0% + 6% (group 5). Blood, urine, and feces are collected and analyzed by radioimmunoassay techniques for estrogens. Cecal contents are analyzed for bacterial beta-D-glucuronidase activity. After 19 weeks on 2o the experimental diets, the rats are killed, and mammary tumors are counted and classified by histologic type. Cumulative tumor incidence is evaluated by the Kaplan-Meier life-table method and the logrank test. Tumor number is evaluated by the chi-squared test of association, and tumor multiplicity is evaluated by the Mantel-Haenszel chi-squared test. All statistical tests are two-tailed.
25 The experiment was undertaken with the belief that the addition of an insoluble (wheat bran) fiber and a water soluble cellulose derivative to a high-fat would provide a tumor-inhibiting effect in this mammary tumor model.
To further determine if colon cancer risk reduction by dietary fiber is 3o possible, a comparison of psyllium (PS), a partially fermentable viscous fiber, to methylcellulose (MC), a nonfermentable viscous fiber, in combinations with wheat bran (WB), in an animal model of colon cancer was conducted.
Methods: Male Fisher 344 rats were randomized into 7 groups of 10 animals each 35 and fed for 26 weeks diets containing one of the following fiber sources (8% w/w) in a semi-purified dietary base: WB, microcrystalline cellulose (C), MC, WB:PS
(1:1), or WB:MC (1:3,1:1, and 3:1). The rats were injected with azoxymethane, 15 mg/kg s.c., on weeks 5 and 6. Rats were killed by C02 inhalation, and colon, liver, and blood samples were obtained. ACFs were quantitated from methylene blue stained, formalin fixed sections by a blinded observer.
Results: As expected, inclusion of PS increased colon weight; MC did not. The proportion of large vs. small ACFs did not vary by colon segment or diet. The WB diet showed the lowest number of ACFs (787, mear>fSE), similar to C (878), while the WB:PS and 3:1 WB:MC diets were significantly higher (1339 and 1069, resp., to p<0.05). MC alone was also significantly higher ( 119t 11 ) vs. WB;
however, 1:1 and 1:3 mixtures of WB and MC were as effective as WB alone. All three combinations of WB with MC yielded significantly fewer ACFs than the WB:PS diet.
Conclusions: It has been hypothesized that fermentation products of soluble fiber, particularly butyrate, are responsible for its protective effect. These results suggesi that fermentation alone cannot account for reduced ACF formation. If fermentation were important, one would not expect the observed outcome for the WB:MC diets in comparison to the WB:PS diet. While not suggesting a particular mechanism of action, sustained viscosity and/or water holding capacity may be critical properties of 2o a soluble fiber with respect to chemoprotection. Furthermore, since the American diet and that of many other cultures typically contains wheat bran, these results support the claim that a supplement which provided only the soluble cellulose derivative would also be protective.
FORMULATIONS
In order to use a water-soluble non-fermentable cellulose derivative as a dietary component, it will normally be used as is, or they may be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
The cellulose derivatives may conveniently be administered orally, in a 3o number of ways. They may be administered in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the final desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of "active 3s ingredient" with which it is to be combined, the route of administration and other well-known variables. The carriers) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra albs, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the Garner or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed. Thus, if a solid to Garner is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, or nonaqueous liquid suspension.
An ei~ective oral dosage regimen in a human would range from about 0.4 to about 30 grams per day, preferably from about 0.5 to about 20 gram/day, more preferably from about 1.0 grams to about 10 grams/day. Preferably, the minimum intake is greater than 2-3 grams/day.
The dry weight of a typical of an adult human diet is about 500 g/day, and should include at least about 25-30 g of fiber. A healthy human diet should contain at least about 5-6% fiber by weight. A typical U. S. diet contains about half this level.
The present invention while making up the fiber intake deficit present in the current human diet with water soluble cellulose derivative will help to reduce cancer risk. It is recognized that while cellulose derivatives may also be protective when added to diets with recommended levels of fiber, the benefit would will most likely be most notable in people who habitually eat less fiber than they should.
It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventions!
3o techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses given per day can be ascertained by those skilled in the art.
A suitable, alternative formulation for use herein includes, but is not limited to the fast dissolving methylcellulose tablets as described in Daggy et al., PCT/US98/17405, filed 8/21/98, or PCT/US98/17440, filed 8/21/98, whose disclosures are incorporated herein by reference in their entirety.
_7_ All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
s The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein axe within the scope of the following claims.
Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples 1o herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.
_g_
w/w) and high (8% w/w) levels of dietary fiber from wheat bran (WB), with high s (8% w/w or >) levels of dietary fiber from a water soluble cellulose derivative (WS) alone or in various combinations with WB, on the induction of colon tumors in Fischer-344 rats following exposure to azoxymethane (AOM). The rats are fed the experimental diets for 2 weeks, and then are given two subcutaneous.
injections of AOM (15 mg/kg body wt./week). Twenty-three weeks following the first injection to of AOM, the incidence of colon tumors in the different dietary groups (12 rats/group) is compared.
In the Alabaster study, results showed that by increasing the dietary fiber concentration of WB from 1 to 8% significantly reduced the number of colon tumors/group. When the influence of 8% dietary fiber from WB on the development 15 of colon tumors was compared with that of psyllium (PS) (WB:PS = 0:100), no significant difference was observed. However, combinations of WB and PS showed a greater protective effect than either WB or PS alone, at comparable levels of dietary fiber. The 50:50 combination of WB and PS showed maximum protection, while 25:75 and 75:25 combinations both produced intermediate effects. None of 2o the diets showed any significant effect on the normal growth of rats. The results indicate that WB and PS fiber alone, and to a greater degree in combination, can offer protection against colon cancer promoted by high fat, low calcium diets.
Therefore, diets that include wheat bran in combination with a water soluble 25 cellulose derivative could be an effective means of reducing colon cancer risk in human populations addicted to high risk western diets.
Example 2 The protective benefit in breast cancer of water soluble fibers could be 3o demonstrated with a study design such as the following. The primary efficacy measures would be total tumor number and multiplicity of mammary adenocarcinomas.
A suitable model for this is the study is shown in Cohen et al., J Natl Cancer Inst 1996 Jul 3;88(13):899-907 Wheat bran and psyllium diets: effects on N-35 methylnitrosourea-induced mammary tumorigenesis in F344 rats, whose disclosure is incorporated by reference herein in its entirety. Using this model but instead substituting a suitable water soluble fiber as taught herein.
This study can evaluate the effect of wheat bran {an insoluble fiber) and a water soluble cellulose (a soluble fiber) alone and in combination on overall estrogen status, on fecal bacterial beta-D-glucuronidase (a key diet-responsive estrogen-deconjugating enzyme) activity, and on the induction of mammary tumors in rats treated with N-methylnitrosourea (~.
1o Methods: One hundred fifty virgin female F344 rats are fed the NIH-07 diet from 28 days of age until 50 days of age; they are then given a single dose (40 mg/kg of body weight) of MNU by tail vein injection. Three days later, they are randomly assigned to one of five experimental dietary groups (30 animals per group).
Soft, white wheat bran (45% dietary fiber content) and water soluble cellulose is added to 15 a modified (high-fat) American Institute of Nutrition (AIN)-76A diet at the following percents, respectively: 12% + 0% (group 1), 8% + 2% (group 2), 6% +
3% (group 3), 4% + 4% (group 4), and 0% + 6% (group 5). Blood, urine, and feces are collected and analyzed by radioimmunoassay techniques for estrogens. Cecal contents are analyzed for bacterial beta-D-glucuronidase activity. After 19 weeks on 2o the experimental diets, the rats are killed, and mammary tumors are counted and classified by histologic type. Cumulative tumor incidence is evaluated by the Kaplan-Meier life-table method and the logrank test. Tumor number is evaluated by the chi-squared test of association, and tumor multiplicity is evaluated by the Mantel-Haenszel chi-squared test. All statistical tests are two-tailed.
25 The experiment was undertaken with the belief that the addition of an insoluble (wheat bran) fiber and a water soluble cellulose derivative to a high-fat would provide a tumor-inhibiting effect in this mammary tumor model.
To further determine if colon cancer risk reduction by dietary fiber is 3o possible, a comparison of psyllium (PS), a partially fermentable viscous fiber, to methylcellulose (MC), a nonfermentable viscous fiber, in combinations with wheat bran (WB), in an animal model of colon cancer was conducted.
Methods: Male Fisher 344 rats were randomized into 7 groups of 10 animals each 35 and fed for 26 weeks diets containing one of the following fiber sources (8% w/w) in a semi-purified dietary base: WB, microcrystalline cellulose (C), MC, WB:PS
(1:1), or WB:MC (1:3,1:1, and 3:1). The rats were injected with azoxymethane, 15 mg/kg s.c., on weeks 5 and 6. Rats were killed by C02 inhalation, and colon, liver, and blood samples were obtained. ACFs were quantitated from methylene blue stained, formalin fixed sections by a blinded observer.
Results: As expected, inclusion of PS increased colon weight; MC did not. The proportion of large vs. small ACFs did not vary by colon segment or diet. The WB diet showed the lowest number of ACFs (787, mear>fSE), similar to C (878), while the WB:PS and 3:1 WB:MC diets were significantly higher (1339 and 1069, resp., to p<0.05). MC alone was also significantly higher ( 119t 11 ) vs. WB;
however, 1:1 and 1:3 mixtures of WB and MC were as effective as WB alone. All three combinations of WB with MC yielded significantly fewer ACFs than the WB:PS diet.
Conclusions: It has been hypothesized that fermentation products of soluble fiber, particularly butyrate, are responsible for its protective effect. These results suggesi that fermentation alone cannot account for reduced ACF formation. If fermentation were important, one would not expect the observed outcome for the WB:MC diets in comparison to the WB:PS diet. While not suggesting a particular mechanism of action, sustained viscosity and/or water holding capacity may be critical properties of 2o a soluble fiber with respect to chemoprotection. Furthermore, since the American diet and that of many other cultures typically contains wheat bran, these results support the claim that a supplement which provided only the soluble cellulose derivative would also be protective.
FORMULATIONS
In order to use a water-soluble non-fermentable cellulose derivative as a dietary component, it will normally be used as is, or they may be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
The cellulose derivatives may conveniently be administered orally, in a 3o number of ways. They may be administered in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the final desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of "active 3s ingredient" with which it is to be combined, the route of administration and other well-known variables. The carriers) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra albs, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the Garner or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed. Thus, if a solid to Garner is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, or nonaqueous liquid suspension.
An ei~ective oral dosage regimen in a human would range from about 0.4 to about 30 grams per day, preferably from about 0.5 to about 20 gram/day, more preferably from about 1.0 grams to about 10 grams/day. Preferably, the minimum intake is greater than 2-3 grams/day.
The dry weight of a typical of an adult human diet is about 500 g/day, and should include at least about 25-30 g of fiber. A healthy human diet should contain at least about 5-6% fiber by weight. A typical U. S. diet contains about half this level.
The present invention while making up the fiber intake deficit present in the current human diet with water soluble cellulose derivative will help to reduce cancer risk. It is recognized that while cellulose derivatives may also be protective when added to diets with recommended levels of fiber, the benefit would will most likely be most notable in people who habitually eat less fiber than they should.
It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventions!
3o techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses given per day can be ascertained by those skilled in the art.
A suitable, alternative formulation for use herein includes, but is not limited to the fast dissolving methylcellulose tablets as described in Daggy et al., PCT/US98/17405, filed 8/21/98, or PCT/US98/17440, filed 8/21/98, whose disclosures are incorporated herein by reference in their entirety.
_7_ All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
s The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein axe within the scope of the following claims.
Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples 1o herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.
_g_
Claims (18)
1. A method of reducing the incidence of colorectal cancers in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a water soluble, non-fermentable cellulose derivative, alone or in combination with an insoluble fiber and/or a soluble fermentable fiber.
2. The method according to Claim 1 wherein the water soluble, non-fermentable cellulose derivative is a cellulose ether which is methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl-methylcellulose, or a combination thereof.
3. The method according to Claim 1 or 2, wherein the soluble fermentable fiber is pysllium.
4. The method according to Claim 1 or 2, wherein the insoluble fiber is wheat bran.
5. The method according to any one of Claims 1 to 4 wherein the water soluble, non-fermentable cellulose derivative is methylcellulose or hydroxypropyl-methylcellulose.
6. The method according to Claim 2 wherein the cellulose is administered as bulk powder, a tablet, or suspension, which optionally contains sugar.
7. The method according to Claim 6 wherein the cellulose is administered in a rapidly disintegrating tablet.
8. The method according to Claim 1 wherein the total daily dosage administered is from about 0.4 gram to 30 grams day.
9. The method according to Claim 8 wherein the total daily dosage administered is from about 1 gram to 10 grams day.
10. A method of reducing the incidence of breast cancer in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a water soluble, non-fermentable cellulose derivative, alone or in combination with an insoluble fiber and/or a soluble fermentable fiber.
11. The method according to Claim 10 wherein the water soluble, non-fermentable cellulose derivative is a cellulose ether which is methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl-methylcellulose, or a combination thereof.
12. The method according to Claim 10 or 11, wherein the soluble fermentable fiber is pysllium.
13. The method according to Claim 10 or 11, wherein the insoluble fiber is wheat bran.
14. The method according to any one of Claims 10 to 13 wherein the water soluble, non-fermentable cellulose derivative is methylcellulose or hydroxypropyl-methylcellulose.
15. The method according to Claim 11 wherein the cellulose is administered as bulk powder, a tablet, or suspension, which optionally contains sugar.
16. The method according to Claim 15 wherein the cellulose is administered in a rapidly disintegrating tablet.
17. The method according to Claim 10 wherein the total daily dosage administered is from about 0.4 gram to 30 grams day.
18. The method according to Claim 17 wherein the total daily dosage administered is from about 1 gram to 10 grams day.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7237098P | 1998-01-23 | 1998-01-23 | |
| US60/072,370 | 1998-01-23 | ||
| PCT/US1999/001377 WO1999037311A1 (en) | 1998-01-23 | 1999-01-21 | Cellulose derivatives and colorectal cancer risk reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2317744A1 true CA2317744A1 (en) | 1999-07-29 |
Family
ID=22107134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002317744A Abandoned CA2317744A1 (en) | 1998-01-23 | 1999-01-21 | Cellulose derivatives and colorectal cancer risk reduction |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1047433A4 (en) |
| JP (1) | JP2002501029A (en) |
| CA (1) | CA2317744A1 (en) |
| WO (1) | WO1999037311A1 (en) |
| ZA (1) | ZA99478B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010506958A (en) * | 2006-10-20 | 2010-03-04 | ダウ グローバル テクノロジーズ インコーポレイティド | Prevention or reduction of oxidative stress or oxidative cytotoxicity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2816726B2 (en) * | 1989-11-10 | 1998-10-27 | カルピス株式会社 | Composition for improving intestinal environment |
| DE69429927T2 (en) * | 1993-11-17 | 2002-11-07 | The Commonwealth Scientific And Industrial Research Organization, Campbell | FATTY ACID SUPPLY SYSTEM |
| AUPO763197A0 (en) * | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
-
1999
- 1999-01-21 JP JP2000528293A patent/JP2002501029A/en active Pending
- 1999-01-21 WO PCT/US1999/001377 patent/WO1999037311A1/en active Application Filing
- 1999-01-21 CA CA002317744A patent/CA2317744A1/en not_active Abandoned
- 1999-01-21 EP EP99903303A patent/EP1047433A4/en not_active Withdrawn
- 1999-01-22 ZA ZA99478A patent/ZA99478B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA99478B (en) | 1999-07-23 |
| JP2002501029A (en) | 2002-01-15 |
| WO1999037311A1 (en) | 1999-07-29 |
| EP1047433A4 (en) | 2009-04-29 |
| EP1047433A1 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reddy et al. | Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. | |
| RU2141844C1 (en) | Pharmaceutical compound | |
| Murai et al. | Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice | |
| Verghese et al. | Dietary inulin suppresses azoxymethane-induced preneoplastic aberrant crypt foci in mature Fisher 344 rats | |
| CA2488723C (en) | Use of pullulan as a slowly digested carbohydrate | |
| KR20020076311A (en) | Inulin Products with Improved Nutritional Properties | |
| CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
| JP2001526671A (en) | Fructan-containing composition for prevention and treatment of colon cancer | |
| US8546341B2 (en) | Compositions and methods for treating bruises | |
| US8426567B2 (en) | Method for enhancing mammalian immunological function | |
| JPH0930987A (en) | Preparation for treating and preventing intractable ulcer, gastritis and dermatitis | |
| CA2347967A1 (en) | Substance for reduction of cholesterol as well as lipids content | |
| EP1897551A1 (en) | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
| CA2317744A1 (en) | Cellulose derivatives and colorectal cancer risk reduction | |
| JP3455633B2 (en) | Agent for preventing or treating ulcerative colitis | |
| CN106822097A (en) | A kind of pharmaceutical composition containing orlistat for losing weight | |
| MXPA00007194A (en) | Cellulose derivatives and colorectal cancer risk reduction | |
| US5985845A (en) | Methods for reducing mortality rates in poultry | |
| Takahashi et al. | Inhibitory effect of microfibril wheat bran on azoxymethane-induced colon carcinogenesis in CF1 mice | |
| WO2022090335A1 (en) | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics | |
| CN106924270A (en) | A kind of pharmaceutical composition with weight losing function containing orlistat | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| JPH09501689A (en) | Reduced absorption of fatty acids | |
| Dwyer et al. | Drug therapy reviews: dietary fiber and fiber supplements in the therapy of gastrointestinal disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |